Oncology clinicians may soon have hundreds of biomarker tests available to them to assist in developing personalized cancer treatments, but some healthcare professionals believe that novel funding approaches for biomarker tests’ studies—a systematic process to move biomarker tests through regulatory agencies and a body of evidence supporting biomarker tests’ benefits—will all be necessary before healthcare system stakeholders accept their use.

In a transaction completed Nov. 7, PerkinElmer purchased Caliper Life Sciences for about $600 million in cash. The Hopkinton, Mass.-based imaging and detection solutions provider will operate within PerkinElmer’s newly formed Life Sciences & Technology Business entity.